University of Pennsylvania

University of California

Celmed Oncology (usa), Inc.

Acidophil, LLC

Oak Ridge National Laboratory

Carlo Ballatore

Amos B Smith, Iii

Virginia Man-Yee Lee

John Q Trojanowski

Kurt R Brunden

Xiaozhao Wang

Francesco Piscitelli

Venkata Ramana Doppalapudi

Ranjan Dohil

Donna Mary Huryn

Joel Desharnais

Palmer Taylor

Angelo J Castellino

Zoran Radic

Adam T Hoye

Chengzao Sun

Maria V Sergeeva

Anne-Marie L Hogan

Sugiyama Shimpei

Onur Atasoylu

Longchuan Huang

Michael James

James Soper

Simon E Aspland

Killian Oukoloff

Xiaolin Cheng

Andrey Kovalevsky

Lukas Gorecki

Donna M Huym

Virginia MY Lee

The disclosure provides for new substituted cysteamine and cystamine compounds, pharmaceutical compositions made thereof, and methods thereof including the treatment of any disease or disorder in a subject that can benefit from one or more of the bioprotective effects of the compounds, including but not limited to, binding of cystine, reducing oxidative stress, increasing adiponectin levels and/or increasing brain-derived neurotrophic factors. Examples of such disease and disorders, include but are not limited to, cystinosis, and fatty liver diseases.

Substituted amino-thiol and amino-disulfide compounds, and uses thereof

In alternative embodiments, provided are uncharged bis-oxime antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibited human acetylcholinesterase (hAChE) in the central nerve system (CNS). In alternative embodiments, provided are pumps, devices, subcutaneous infusion devices, continuous subcutaneous infusion devices, infusion pens, needles, reservoirs, ampoules, a vial, a syringe, a cartridge, a disposable pen or jet injector, a prefilled pen or a syringe or a cartridge, a cartridge or a disposable pen or jet injector, a two chambered or multi-chambered pump, a syringe, a cartridge or a pen or a jet injector, comprising a compound as provided herein.

Centrally active and orally bioavailable uncharged bisoxime antidotes for organophosphate poisoning and methods for making and using them

The present disclosure provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Rx-R8 are defined herein. Also provided are compositions comprising a compound described herein and a pharmaceutically effective excipient, methods of stabilizing microtubules in a patient comprising administering to the patient a microtubule-stabilizing amount of a compound described herein, methods of treating cancer in a patient comprising administering to the patient a therapeutically effective amount of a compound described herein, and methods of treating a neurodegenerative disease in a patient comprising administering to the patient a therapeutically effective amount of a compound described herein. 

Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules

The present invention is directed to triazolopyrimidine, phenylpyrimidine, pyridopyridazine, and pyridotriazine compounds which are microtubule-stabilizing compounds and their use in the treatment of neurodegenerative disorders, in particular, tauopathies, such as for example, Alzheimer's disease, frontotemporal lobar degeneration, Pick's disease, progressive supranuclear palsy (PSP), and corticobasal degeneration. In addition, the compounds of the invention may be useful for other diseases where tau pathology is a comorbidity or where microtubule function is compromised, for example, schizophrenia, Parkinson's disease (PD), PD with dementia, Lewy body disease with dementia, and amyotrophic lateral sclerosis.

Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies

The present invention is directed to compounds of formula I: wherein A is n is 0, 1, or 2; m is 0 or 1; Ris H or Calkyl and Ris H, Calkyl, Calkaryl, aryl, or heteroaryl; and X is O or NH. Tautomers, enantiomers, and diastereomers, as well as pharmaceutically acceptable salt forms, of compounds of formula I are also within the scope of the invention. Methods of preparing and using the compounds of formula I are also described.  

Cycloalkyl-dione derivatives and methods of their use

The present invention relates to novel TP receptor antagonists, which optionally cross the blood-brain barrier of a mammal. The invention also provides methods for treating a disorder related to activation of TP receptor utilizing the compounds of the invention.

Thromboxane A2 (TP) receptor antagonists

The present invention is directed to carboxylic acid-containing pharmaceutical compounds where the carboxylic acid moieties have been substituted with cycloalkyl-dione derivatives, as well as tautomers and pharmaceutically acceptable salt forms thereof. These bioisosteric replacements improve the compound's ability to effectively cross the blood brain barrier and result in improved pharmacokinetic, toxicological, and/or safety profiles.

Provided herein are C-10 taxane carbamates and pharmaceutically acceptable derivatives thereof. In certain embodiments, provided herein are compounds, compositions and methods for treating cancer and taupathy.

C-10 carbamates of taxanes

The invention provides compounds and methods for using them to inhibit the growth of microorganism that expresses Peptide Deformylase, the compounds having the general formula:

Peptide deformylase activated prodrugs

Growing community of inventors

Philadelphia, PA, United States of America

Carlo Ballatore